Colistin is an, antibiotic used to treat carbapenem-resistant Acinetobacter baumannii complex (CRABC) infection. However, colistin is well known for its nephrotoxicity. To accurately assess the effects of colistin on acute kidney injury (AKI) and 28-day mortality, we investigated the risk factors associated with AKI and mortality in patients with CRABC bacteremia who received or never received colistin. Patients with CRABC bacteremia aged ≥18 years were retrospectively identified for 3 years at five tertiary teaching hospitals. AKI was defined by using the Kidney Disease Improving Global Outcomes criteria. AKI developed in 103 (34.9%) of the 295 patients enrolled patients. AKI developed more frequently in patients who received colistin than in patients who did not (46.7% vs. 29.5%, p = 0.004). Multivariate analysis showed that intravenous colistin usage was an independent risk factor for AKI in these patients. Nonfatal disease, catheter-related bloodstream infection, and administration of colistin were protective factors for 28-day mortality. However, the sequential organ failure assessment score and AKI were associated with poor outcomes. In conclusion, colistin may be a double-edged sword; although it causes AKI, it also reduces 28-day mortality in patients with CRABC bacteremia. Therefore, colistin administration as an appropriate antibiotic may improve CRABC bacteremia prognosis, despite its nephrotoxicity.
Get full access to this article
View all access options for this article.
References
1.
PhillipsM.2015. Acinetobacter species. In J.E. Bennett, R. Dolin and M.J. Blaser (eds.), Mandell, Douglas, and Bennett's principles and practice of infectious diseases. Elsevier Saunders Philadelphia,, PA, 2015.
2.
PelegA.Y., SeifertH., and PatersonD.L.. 2008. Acinetobacter baumannii: emergence of a successful pathogen. Clin. Microbiol. Rev. 21:538–582.
3.
Munoz-PriceL.S., ArheartK., NordmannP., et al.2013. Eighteen years of experience with Acinetobacter baumannii in a tertiary care hospital. Crit. Care. Med. 41:2733–2742.
4.
RhombergP.R., and JonesR.N.. 2009. Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999–2008). Diagn. Microbiol. Infect. Dis. 65:414–426.
5.
ReddyT., ChopraT., MarchaimD., et al.2010. Trends in antimicrobial resistance of Acinetobacter baumannii isolates from a metropolitan Detroit health system. Antimicrob. Agents. Chemother. 54:2235–2238.
6.
HidronA.I, EdwardsJ.R, PatelJ., et al.2008. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007. Infect. Control. Hosp. Epidemiol. 29:996–1011.
7.
KimD., AhnJ.Y, LeeC.H, et al.2017. Increasing resistance to extended-spectrum cephalosporins, fluoroquinolone, and carbapenem in Gram-negative bacilli and the emergence of carbapenem non-susceptibility in Klebsiella pneumoniae: analysis of Korean Antimicrobial Resistance Monitoring System (KARMS) data from 2013 to 2015. Ann. Lab. Med. 37:231–239.
8.
LeeH., YoonE.J, KimD., et al.2018. Antimicrobial resistance of major clinical pathogens in South Korea, May 2016 to April 2017: first one-year report from Kor-GLASS. Euro. Surveill. 23:1800047.
9.
FreireM.P., de Oliveira GarciaD., GarciaC.P, et al.2016. Bloodstream infection caused by extensively drug-resistant Acinetobacter baumannii in cancer patients: high mortality associated with delayed treatment rather than with the degree of neutropenia. Clin. Microbiol. Infect. 22:352–358.
10.
ParkS.Y., LeeE.J, KimT., et al.2018. Early administration of appropriate antimicrobial agents to improve the outcome of carbapenem-resistant Acinetobacter baumannii complex bacteraemic pneumonia. Int. J. Antimicrob. Agents. 51:407–412.
11.
KwonK.H., OhJ.Y, YoonY.S, et al.2015. Colistin treatment in carbapenem-resistant Acinetobacter baumannii pneumonia patients: incidence of nephrotoxicity and outcomes. Int. J. Antimicrob. Agents. 45:605–609.
12.
NutmanA., GlickR., TemkinE., et al.2014. A case-control study to identify predictors of 14-day mortality following carbapenem-resistant Acinetobacter baumannii bacteraemia. Clin. Microbiol. Infect. 20:O1028–O1034.
13.
BatirelA., BalkanII, KarabayO., et al.2014. Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections. Eur. J. Clin. Microbiol. Infect. Dis. 33:1311–1322.
14.
ZavasckiA.P., and NationR.L.. 2017. Nephrotoxicity of polymyxins: is there any difference between colistimethate and polymyxin B? Antimicrob. Agents Chemother. 61:e02319-16.
15.
NationR.L., VelkovT., and LiJ.. 2014. Colistin and polymyxin B: peas in a pod, or chalk and cheese? Clin. Infect. Dis. 59:88–94.
16.
BergenP.J., LiJ., RaynerC.R, and NationR.L.. 2006. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob. Agents. Chemother. 50:1953–1958.
17.
PogueJ.M., LeeJ., MarchaimD., et al.2011. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin. Infect. Dis. 53:879–884.
18.
HartzellJ.D., NeffR., AkeJ., et al.2009. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin. Infect. Dis. 48:1724–1728.
19.
RoccoM., MontiniL., AlessandriE., et al.2013. Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study. Crit. Care. 17:R174.
20.
TigenE.T., KoltkaE.N, DogruA., GuraM., and VahabaogluH.. 2016. The risk factors of colistin methanesulfonate associated nephrotoxicity. Indian J. Crit. Care Med. 20:353–356.
21.
FalagasM.E., FragoulisK.N, KasiakouS.K, SermaidisG.J, and MichalopoulosA.. 2005. Nephrotoxicity of intravenous colistin: a prospective evaluation. Int. J. Antimicrob. Agents. 26:504–507.
22.
BellomoR., RoncoC., KellumJ.A, MehtaR.L, PalevskyP., and Acute Dialysis Quality Initiative workgroup. 2004. Acute renal failure—definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit. Care. 8:R204–R212.
23.
MehtaR.L., KellumJ.A, ShahS.V, et al.2007. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit. Care. 11:R31.
24.
KhwajaA.2012. KDIGO clinical practice guidelines for acute kidney injury. Nephron. Clin. Pract. 120:c179–c184.
25.
BrownM.L., MotschJ., KayeK.S, et al.2020. Evaluation of renal safety between imipenem/relebactam and colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections in the randomized, phase 3 RESTORE-IMI 1 study. Open. Forum. Infect. Dis. 7:ofaa054.
26.
RigattoM.H., BehleT.F, FalciD.R, et al.2015. Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study. J. Antimicrob. Chemother. 70:1552–1557.
27.
WilliamR., and McCabeG.G.J. 1962. Gram-negative bacteremia. l. Etiology and ecology. Arch. Intern. Med. 110:847–855.
28.
HoranT.C., AndrusM., and DudeckM.A.. 2008. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am. J. Infect. Control. 36:309–332.
29.
KnausW.A., DraperE.A, WagnerD.P, and ZimmermanJ.E.. 1985. APACHE II: a severity of disease classification system. Crit. Care Med. 13:818–829.
30.
VincentJ.L., MorenoR., TakalaJ., et al.1996. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intens. Care Med. 22:707–710.
31.
KoW.C., LeeN.Y, SuS.C, et al.2008. Oligonucleotide array-based identification of species in the Acinetobacter calcoaceticus-A. baumannii complex in isolates from blood cultures and antimicrobial susceptibility testing of the isolates. J. Clin. Microbiol. 46:2052–2059.
32.
ChuangY.C., ShengW.H, LiS.Y, et al.2011. Influence of genospecies of Acinetobacter baumannii complex on clinical outcomes of patients with acinetobacter bacteremia. Clin. Infect. Dis. 52:352–360.
33.
Institute Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 30th ed. Clinical and Laboratory Standards Institute, Wayne, PA, 2020.
34.
OmraniA.S., AlfahadW.A, ShoukriM.M, et al.2015. High dose intravenous colistin methanesulfonate therapy is associated with high rates of nephrotoxicity; a prospective cohort study from Saudi Arabia. Ann. Clin. Microbiol. Antimicrob. 14:3.
35.
OliotaA.F., PenteadoS.T, ToninF.S, Fernandez-LlimosF., and SanchesA.C.. 2019. Nephrotoxicity prevalence in patients treated with polymyxins: a systematic review with meta-analysis of observational studies. Diagn. Microbiol. Infect. Dis. 94:41–49.
36.
KimT., ParkK.H, YuS.N, et al.2019. Early intravenous colistin therapy as a favorable prognostic factor for 28-day mortality in patients with CRAB bacteremia: a multicenter propensity score-matching analysis. J. Korean Medical Science. 34:e256.
37.
PerlT.M., DvorakL., HwangT., and WenzelR.P.. 1995. Long-term survival and function after suspected gram-negative sepsis. JAMA. 274:338–345.
38.
Ruiz-RuigómezM., Fernández-RuizM., San-JuanR., et al.2020. Impact of duration of antibiotic therapy in central venous catheter-related bloodstream infection due to Gram-negative bacilli. J. Antimicrob. Chemother. 75:3049–3055.
39.
LeeY.M., MoonC., and ParkK.H.. 2020. Is short-term antibiotic therapy safe in patients with central venous catheter-related Gram-negative bacteraemia? J. Antimicrob. Chemother, 76:539–541.
40.
InchaiJ., PothiratC., BumroongkitC., LimsukonA., KhositsakulchaiW., and LiwsrisakunC.. 2015. Prognostic factors associated with mortality of drug-resistant Acinetobacter baumannii ventilator-associated pneumonia. J. Intens. Care. 3:9.
41.
ChenS.J., ChaoT.F, ChiangM.C, et al.2011. Prediction of patient outcome from Acinetobacter baumannii bacteremia with Sequential Organ Failure Assessment (SOFA) and Acute Physiology and Chronic Health Evaluation (APACHE) II scores. Intern. Med. 50:871–877.
42.
TsaiT.Y., ChienH., TsaiF.C, et al.2017. Comparison of RIFLE, AKIN, and KDIGO classifications for assessing prognosis of patients on extracorporeal membrane oxygenation. J. Formos. Med. Assoc. 116:844–851.
43.
LeviT.M., de S.P, SouzaS.P, de MagalhãesJ.G, et al.2013. Comparison of the RIFLE, AKIN and KDIGO criteria to predict mortality in critically ill patients. Rev. Bras. Ter. Intensiva. 25:290–296.
44.
de MendonçaA., VincentJ.L, SuterP.M, et al.2000. Acute renal failure in the ICU: risk factors and outcome evaluated by the SOFA score. Intensive Care Med. 26:915–921.
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
